Strategic partnerships Microbiotica has established collaborations with Cancer Research UK, Cambridge University Hospitals, Genentech/Roche, and the University of Adelaide, indicating a strong open-innovation posture and potential co-development or licensing opportunities for microbiome-based therapies and biomarkers.

Clinical-stage focus With a pipeline of live bacterial therapeutics and biomarkers across IBD, immuno-oncology, and gut epithelial barrier repair, the company presents adjacent markets for contract research, external development partnerships, and early-access programs for investigational microbiome medicines.

leadership momentum Recent leadership appointment of a Chief Medical Officer and ongoing clinical progress suggest readiness for more robust clinical collaborations, advisory roles, and strategic finance discussions that can unlock milestone-driven partnerships.

Scale-ready capabilities World-leading microbiome culture collection, proprietary reference genome database, and advanced bioinformatics position Microbiotica as a valuable partner for mechanistic studies, diagnostic development, and data-centric collaboration with pharma and biotech companies.

Global investor backing Significant Series B funding and high-profile investors (Tencent, Cambridge Innovation Capital, Seventure Partners, IP Group) indicate strong financial backing and credibility, reducing channel risk for co-development deals and enabling larger-scale partnerships.